AI Engines For more Details: Perplexity Kagi Labs You
Eye Inflammation: Rimexolone is indicated for the treatment of inflammation of the eye structures, including the conjunctiva, cornea, and anterior segment of the eye. It is commonly used to manage conditions such as anterior uveitis, iritis, and keratitis.
Allergic Conjunctivitis: Rimexolone may be prescribed for the treatment of allergic conjunctivitis, an allergic reaction affecting the conjunctiva (the thin, transparent membrane covering the white part of the eye).
Postoperative Inflammation: Following ocular surgery, rimexolone can help reduce inflammation and promote healing. It is often used after procedures such as cataract surgery or refractive surgery to minimize postoperative inflammation and discomfort.
Steroid-Responsive Conditions: Rimexolone is effective in managing steroid-responsive ocular conditions, where inflammation plays a significant role in disease pathogenesis and symptomatology.
Side Effects: While rimexolone is generally well-tolerated when used appropriately in ophthalmic applications, it can still cause side effects, especially with prolonged or high-dose use. Common side effects may include temporary burning or stinging upon instillation, blurred vision, increased intraocular pressure (IOP), and delayed wound healing.
Increased Intraocular Pressure (IOP): Prolonged use of rimexolone or other corticosteroids in the eye can lead to elevated intraocular pressure, which may increase the risk of glaucoma or worsen existing glaucoma in susceptible individuals. Therefore, patients using rimexolone should be monitored regularly for changes in intraocular pressure.
Cataract Formation: Long-term use of corticosteroids like rimexolone in the eye may contribute to the development or exacerbation of cataracts, particularly in predisposed individuals.
Infection Risk: Corticosteroids, including rimexolone, can mask the signs of ocular infections or exacerbate existing infections. Patients should be cautioned about the potential risk of secondary infections and advised to seek medical attention if they experience worsening symptoms or new ocular complaints while using rimexolone.
Hypersensitivity Reactions: Some individuals may experience hypersensitivity or allergic reactions to rimexolone or its components. Patients should discontinue use and seek medical advice if they develop signs of allergic reaction, such as itching, redness, swelling, or rash.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Escherichia | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
| 0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
| 0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
| 0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
| 0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
| 0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
| 0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
| 0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
| 0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
| 0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
| 0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
| 0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
| 0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O111 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O121 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O155 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O177 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O26 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O3 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O5 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O86 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O91 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O103 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O78 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O43 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O119 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O157 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O145 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
| 0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
| 0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
| 0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
| 0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
| 0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
| 0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
| 0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
| 0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
| 0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
| 0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
| 0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
| 0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli H20 | serotype | Decreases |
| 0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
| 0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
| 0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
| 0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
| 0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
| 0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
| 0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
| 0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
| 0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Escherichia coli | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.6 | 0.3 | 1 |
| ADHD | 3.4 | 0.9 | 2.78 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 2 | 1.2 | 0.67 |
| Allergies | 3.3 | 1.9 | 0.74 |
| Allergy to milk products | 1.1 | 1.6 | -0.45 |
| Alopecia (Hair Loss) | 0.2 | 0.2 | |
| Alzheimer's disease | 5.2 | 4.7 | 0.11 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.3 | 1.1 | 1.09 |
| Ankylosing spondylitis | 1.8 | 0.9 | 1 |
| Anorexia Nervosa | 1.3 | 2.2 | -0.69 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.3 | 0.33 |
| Asthma | 2.9 | 1.8 | 0.61 |
| Atherosclerosis | 1.5 | 1.5 | 0 |
| Atrial fibrillation | 2.4 | 2.2 | 0.09 |
| Autism | 5.3 | 5.4 | -0.02 |
| Autoimmune Disease | 1.2 | 0.8 | 0.5 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.4 | 1.4 | |
| Bipolar Disorder | 2.2 | 1.4 | 0.57 |
| Brain Trauma | 0.6 | 1.4 | -1.33 |
| Breast Cancer | 1.3 | 0.3 | 3.33 |
| Cancer (General) | 0.6 | 0.7 | -0.17 |
| Carcinoma | 4 | 1.6 | 1.5 |
| Celiac Disease | 1.5 | 2 | -0.33 |
| Cerebral Palsy | 0.9 | 1.1 | -0.22 |
| Chronic Fatigue Syndrome | 3.3 | 3.5 | -0.06 |
| Chronic Kidney Disease | 2.3 | 1.5 | 0.53 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.4 | 1.4 | 0 |
| Chronic Urticaria (Hives) | 1 | 0.4 | 1.5 |
| Coagulation / Micro clot triggering bacteria | 1.4 | 1.1 | 0.27 |
| Cognitive Function | 2.1 | 1.4 | 0.5 |
| Colorectal Cancer | 6.7 | 2.2 | 2.05 |
| Constipation | 1.7 | 0.8 | 1.13 |
| Coronary artery disease | 1.6 | 1.9 | -0.19 |
| COVID-19 | 5.1 | 5.5 | -0.08 |
| Crohn's Disease | 6.2 | 3.4 | 0.82 |
| Cushing's Syndrome (hypercortisolism) | 0.7 | -0.7 | |
| cystic fibrosis | 0.7 | 1.3 | -0.86 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 2.7 | 1.4 | 0.93 |
| Denture Wearers Oral Shifts | 1 | 1 | |
| Depression | 7.6 | 5.5 | 0.38 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.2 | 1 | 0.2 |
| Endometriosis | 2.3 | 1.5 | 0.53 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 2.1 | 1.4 | 0.5 |
| erectile dysfunction | 1.2 | 0.3 | 3 |
| Fibromyalgia | 1.8 | 2.6 | -0.44 |
| Functional constipation / chronic idiopathic constipation | 3.6 | 3 | 0.2 |
| gallstone disease (gsd) | 1.7 | 1.2 | 0.42 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | 0.3 | 4 |
| Generalized anxiety disorder | 2.3 | 1.8 | 0.28 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.8 | 0.9 | 2.11 |
| Graves' disease | 1.3 | 2 | -0.54 |
| Gulf War Syndrome | 0.6 | 0.7 | -0.17 |
| Halitosis | 1.5 | 0.3 | 4 |
| Hashimoto's thyroiditis | 2 | 0.9 | 1.22 |
| Heart Failure | 3.2 | 1.9 | 0.68 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 0.7 | 0.6 | 0.17 |
| hypercholesterolemia (High Cholesterol) | 0.4 | 0.1 | 3 |
| hyperglycemia | 1.4 | 1.2 | 0.17 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.6 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 2.6 | 3.2 | -0.23 |
| Hypothyroidism | 0.1 | 0.9 | -8 |
| Hypoxia | 1.8 | 0.3 | 5 |
| IgA nephropathy (IgAN) | 1.9 | 1.5 | 0.27 |
| Inflammatory Bowel Disease | 4.9 | 4.5 | 0.09 |
| Insomnia | 1.3 | 1.9 | -0.46 |
| Intelligence | 1.1 | 0 | 0 |
| Intracranial aneurysms | 1.3 | 0.6 | 1.17 |
| Irritable Bowel Syndrome | 4.1 | 3.6 | 0.14 |
| ischemic stroke | 1.8 | 1.7 | 0.06 |
| Liver Cirrhosis | 5.2 | 3.5 | 0.49 |
| Long COVID | 4.8 | 3.8 | 0.26 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1.5 | 0.4 | 2.75 |
| Lymphoma | 0.9 | 0.9 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 0.3 | 1.2 | -3 |
| ME/CFS without IBS | 1.2 | 0.7 | 0.71 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.6 | 0.6 | 0 |
| Metabolic Syndrome | 5.4 | 4.8 | 0.13 |
| Mood Disorders | 7.3 | 4.9 | 0.49 |
| multiple chemical sensitivity [MCS] | 0.5 | 0.5 | |
| Multiple Sclerosis | 4.9 | 3.1 | 0.58 |
| Multiple system atrophy (MSA) | 0.7 | 0.6 | 0.17 |
| myasthenia gravis | 0.9 | 0.5 | 0.8 |
| neuropathic pain | 0.3 | 1.8 | -5 |
| Neuropathy (all types) | 0.6 | 2.1 | -2.5 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.9 | 2.7 | 0.07 |
| NonCeliac Gluten Sensitivity | 1 | 0.6 | 0.67 |
| Obesity | 6.1 | 5.2 | 0.17 |
| obsessive-compulsive disorder | 3.1 | 2 | 0.55 |
| Osteoarthritis | 1.6 | 1.2 | 0.33 |
| Osteoporosis | 2 | 1 | 1 |
| pancreatic cancer | 2.1 | 0.6 | 2.5 |
| Parkinson's Disease | 5.1 | 4.1 | 0.24 |
| Polycystic ovary syndrome | 4.7 | 2.7 | 0.74 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.3 | 0.4 | -0.33 |
| primary biliary cholangitis | 0.3 | 1 | -2.33 |
| Primary sclerosing cholangitis | 1.6 | 1.3 | 0.23 |
| Psoriasis | 1.2 | 2.2 | -0.83 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.7 | 2.5 | 0.88 |
| Rosacea | 0.6 | 0.8 | -0.33 |
| Schizophrenia | 4.3 | 2.2 | 0.95 |
| scoliosis | 0.4 | 0.6 | -0.5 |
| Sjögren syndrome | 1.6 | 1.8 | -0.13 |
| Sleep Apnea | 1.2 | 1.7 | -0.42 |
| Slow gastric motility / Gastroparesis | 0.7 | 0.3 | 1.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.3 | 1.3 | |
| Stress / posttraumatic stress disorder | 2 | 2.5 | -0.25 |
| Systemic Lupus Erythematosus | 3.3 | 1.4 | 1.36 |
| Tic Disorder | 1.3 | 0.3 | 3.33 |
| Tourette syndrome | 0.4 | 0.3 | 0.33 |
| Type 1 Diabetes | 3.1 | 2.2 | 0.41 |
| Type 2 Diabetes | 6.2 | 4.1 | 0.51 |
| Ulcerative colitis | 3.2 | 4.3 | -0.34 |
| Unhealthy Ageing | 3 | 2.2 | 0.36 |
| Vitiligo | 1.8 | 1.4 | 0.29 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]